# IRCCS Humanitas Research Hospital

Source: https://onco.cc/institutions/humanitas/  
OnCo record `humanitas` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Milan research hospital known for Alberto Mantovani's work on tumour-associated macrophages and for stereotactic radiotherapy and liver cancer trials.

## Summary

Humanitas Research Hospital, founded in 1996 in Rozzano, is a private IRCCS teaching hospital with its own Humanitas University. Alberto Mantovani, its scientific director, established the concept of cancer-related inflammation and the role of tumour-associated macrophages, complement and pentraxin 3 in tumour progression. The Humanitas Cancer Center under Armando Santoro has been a major site for hepatocellular carcinoma and biliary cancer trials, including with Lorenza Rimassa, and Marta Scorsetti's radiotherapy department is a leader in stereotactic body radiotherapy for oligometastatic disease. The hospital also runs haematology, thoracic and colorectal surgery and an early-phase unit, and holds OECI accreditation.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Humanitas Cancer Center; Istituto Clinico Humanitas
- City: Rozzano (Milan), IT
- Type: hospital
- Website: https://www.humanitas.net

## Sources

- Homepage: https://www.humanitas.net
- Cancer Center: https://www.humanitas.net/cancer-center/

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Radiation Therapy](https://onco.cc/fronts/radiation/)
- technologies: [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- institutions: [Fondazione IRCCS Policlinico San Matteo](https://onco.cc/institutions/policlinico-san-matteo/), [Fondazione Poliambulanza](https://onco.cc/institutions/fondazione-poliambulanza/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/)
- terms: [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Oligometastatic disease](https://onco.cc/terms/oligometastatic/)
- people: [Armando Santoro](https://onco.cc/people/armando-santoro/), [Domenica Lorusso](https://onco.cc/people/domenica-lorusso/), [Riccardo Bui](https://onco.cc/people/riccardo-bui/), [Simona Sancini](https://onco.cc/people/simona-sancini/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/)
- key papers: [Balkwill and Mantovani 2001: inflammation and cancer, back to Virchow?](https://onco.cc/key-papers/paper-balkwill-mantovani-inflammation-virchow-lancet-2001/)

---
JSON: https://onco.cc/api/v1/entities/humanitas.json